NextCure Launches Early-Stage Study For NC762 In Solid Tumor Settings

by Vandana Singh, Benzinga Editor

July 7, 2021 8:06 AM | 1 min read |

NextCure Inc NXTC has initiated the clinical trial of its third product candidate, NC762, a humanized B7-H4 monoclonal antibody.
The Phase 1 dose-escalation portion of this Phase 1/2 open-label trial will evaluate the safety and tolerability of NC762 in patients with advanced or metastatic solid tumors and determine its maximum tolerated dose.
After a recommended dose for the Phase 2 portion of the trial is determined, NC762 will be evaluated in select tumor types.
A B7-H4 Immunohistochemistry (IHC) assay has been developed and will be used for patient selection in Phase 2.
Price Action: NXTC shares closed at $7.89 on Tuesday.

Posted In: Biotech News Health Care General Briefs Phase 1 Trial Solid Tumor

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.